Skip to main content
Erschienen in: Journal of Neurology 4/2024

27.12.2023 | Original Communication

Clinical features and neurobiochemical mechanisms of olfactory dysfunction in patients with Parkinson disease

verfasst von: Ruidan Wang, Tenghong Lian, Mingyue He, Peng Guo, Shuyang Yu, Lijun Zuo, Yang Hu, Wei Zhang

Erschienen in: Journal of Neurology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to investigate clinical features, influencing factors and neurobiochemical mechanisms of olfactory dysfunction (OD) in Parkinson disease (PD). Total 39 patients were divided into the PD with OD (PD–OD) and PD with no OD (PD–nOD) groups according to overall olfactory function, including threshold, discrimination and identification, assessed by Sniffin’ Sticks test. Motor function and non-motor symptoms were rated by multiple scales. Dopamine, acetylcholine, norepinephrine and 5-hydroxytryptamine levels in cerebrospinal fluid (CSF) were measured. We found that the PD–OD group showed significantly lower score of Montreal Cognitive Assessment Scale, higher scores of rapid eye movement sleep behavior disorder (RBD) Screening Questionnaire and Epworth Sleepiness Scale than the PD–nOD group (p < 0.05). RBD Screening Questionnaire score was independently associated with the scores of overall olfactory function and discrimination (p < 0.05). Dopamine and acetylcholine levels in CSF from the PD–OD group was significantly lower than that from the PD–nOD group (p < 0.05). Dopamine and acetylcholine levels in CSF were significantly and positively correlated with the scores of overall olfactory function, threshold, discrimination and identification in PD patients (p < 0.05). RBD Screening Questionnaire score was significantly and negatively correlated with acetylcholine level in CSF in PD patients with poor olfactory detection (p < 0.05). This investigation reveals that PD–OD is associated with cognitive impairment, probable RBD and excessive daytime sleepiness. PD–OD is correlated with the decreased levels of dopamine and acetylcholine in CSF. RBD is an independent influencing factor of overall olfactory function and discrimination, and the decreased acetylcholine level in CSF may be the common neurobiochemical basis of RBD and OD in PD patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Berendse HW, Roos DS, Raijmakers P, Doty RL (2011) Motor and non-motor correlates of olfactory dysfunction in Parkinson’s disease. J Neurol Sci 310:21–24PubMedCrossRef Berendse HW, Roos DS, Raijmakers P, Doty RL (2011) Motor and non-motor correlates of olfactory dysfunction in Parkinson’s disease. J Neurol Sci 310:21–24PubMedCrossRef
2.
Zurück zum Zitat Kanavou S, Pitz V, Lawton MA, Malek N, Grosset KA, Morris HR et al (2021) Comparison between four published definitions of hyposmia in Parkinson’s disease. Brain Behav 11:e2258PubMedPubMedCentralCrossRef Kanavou S, Pitz V, Lawton MA, Malek N, Grosset KA, Morris HR et al (2021) Comparison between four published definitions of hyposmia in Parkinson’s disease. Brain Behav 11:e2258PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Chen H, Shrestha S, Huang X, Jain S, Guo X, Tranah GJ et al (2017) Olfaction and incident Parkinson disease in US white and black older adults. Neurology 89:1441–1447PubMedPubMedCentralCrossRef Chen H, Shrestha S, Huang X, Jain S, Guo X, Tranah GJ et al (2017) Olfaction and incident Parkinson disease in US white and black older adults. Neurology 89:1441–1447PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Krismer F, Pinter B, Mueller C, Mahlknecht P, Nocker M, Reiter E et al (2017) Sniffing the diagnosis: olfactory testing in neurodegenerative parkinsonism. Parkinsonism Relat Disord 35:36–41PubMedCrossRef Krismer F, Pinter B, Mueller C, Mahlknecht P, Nocker M, Reiter E et al (2017) Sniffing the diagnosis: olfactory testing in neurodegenerative parkinsonism. Parkinsonism Relat Disord 35:36–41PubMedCrossRef
5.
Zurück zum Zitat Doty RL, Hawkes CH (2019) Chemosensory dysfunction in neurodegenerative diseases. Handb Clin Neurol 164:325–360PubMedCrossRef Doty RL, Hawkes CH (2019) Chemosensory dysfunction in neurodegenerative diseases. Handb Clin Neurol 164:325–360PubMedCrossRef
6.
Zurück zum Zitat Shill HA, Zhang N, Driver-Dunckley E, Mehta S, Adler CH, Beach TG (2021) Olfaction in neuropathologically defined progressive supranuclear palsy. Mov Disord 36:1700–1704PubMedPubMedCentralCrossRef Shill HA, Zhang N, Driver-Dunckley E, Mehta S, Adler CH, Beach TG (2021) Olfaction in neuropathologically defined progressive supranuclear palsy. Mov Disord 36:1700–1704PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Hoyles K, Sharma JC (2013) Olfactory loss as a supporting feature in the diagnosis of Parkinson’s disease: a pragmatic approach. J Neurol 260:2951–2958PubMedCrossRef Hoyles K, Sharma JC (2013) Olfactory loss as a supporting feature in the diagnosis of Parkinson’s disease: a pragmatic approach. J Neurol 260:2951–2958PubMedCrossRef
8.
Zurück zum Zitat Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ (2006) Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:968–975PubMedCrossRef Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ (2006) Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:968–975PubMedCrossRef
9.
10.
Zurück zum Zitat Haehner A, Hummel T, Reichmann H (2014) A clinical approach towards smell loss in Parkinson’s disease. J Parkinsons Dis 4:189–195PubMedCrossRef Haehner A, Hummel T, Reichmann H (2014) A clinical approach towards smell loss in Parkinson’s disease. J Parkinsons Dis 4:189–195PubMedCrossRef
11.
Zurück zum Zitat Rahayel S, Frasnelli J, Joubert S (2012) The effect of Alzheimer’s disease and Parkinson’s disease on olfaction: a meta-analysis. Behav Brain Res 231:60–74PubMedCrossRef Rahayel S, Frasnelli J, Joubert S (2012) The effect of Alzheimer’s disease and Parkinson’s disease on olfaction: a meta-analysis. Behav Brain Res 231:60–74PubMedCrossRef
12.
Zurück zum Zitat Lee DH, Oh JS, Ham JH, Lee JJ, Lee I, Lee PH et al (2015) Is normosmic Parkinson disease a unique clinical phenotype? Neurology 85:1270–1275PubMedCrossRef Lee DH, Oh JS, Ham JH, Lee JJ, Lee I, Lee PH et al (2015) Is normosmic Parkinson disease a unique clinical phenotype? Neurology 85:1270–1275PubMedCrossRef
13.
Zurück zum Zitat Iijima M, Kobayakawa T, Saito S, Osawa M, Tsutsumi Y, Hashimoto S et al (2011) Differences in odor identification among clinical subtypes of Parkinson’s disease. Eur J Neurol 18:425–429PubMedCrossRef Iijima M, Kobayakawa T, Saito S, Osawa M, Tsutsumi Y, Hashimoto S et al (2011) Differences in odor identification among clinical subtypes of Parkinson’s disease. Eur J Neurol 18:425–429PubMedCrossRef
14.
Zurück zum Zitat Double KL, Rowe DB, Hayes M, Chan DK, Blackie J, Corbett A et al (2003) Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol 60:545–549PubMedCrossRef Double KL, Rowe DB, Hayes M, Chan DK, Blackie J, Corbett A et al (2003) Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol 60:545–549PubMedCrossRef
15.
Zurück zum Zitat Huisman E, Uylings HB, Hoogland PV (2004) A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson’s disease. Mov Disord 19:687–692PubMedCrossRef Huisman E, Uylings HB, Hoogland PV (2004) A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson’s disease. Mov Disord 19:687–692PubMedCrossRef
16.
Zurück zum Zitat Jiang S, Berger S, Hu Y, Bartsch D, Tian Y (2020) Alterations of the motor and olfactory functions related to parkinson’s disease in transgenic mice with a VMAT2-deficiency in dopaminergic neurons. Front Neurosci 14:356PubMedPubMedCentralCrossRef Jiang S, Berger S, Hu Y, Bartsch D, Tian Y (2020) Alterations of the motor and olfactory functions related to parkinson’s disease in transgenic mice with a VMAT2-deficiency in dopaminergic neurons. Front Neurosci 14:356PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Oh YS, Kim JS, Hwang EJ, Lyoo CH (2018) Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson’s disease. Parkinsonism Relat Disord 56:47–51PubMedCrossRef Oh YS, Kim JS, Hwang EJ, Lyoo CH (2018) Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson’s disease. Parkinsonism Relat Disord 56:47–51PubMedCrossRef
18.
Zurück zum Zitat Berkowicz DA, Trombley PQ (2000) Dopaminergic modulation at the olfactory nerve synapse. Brain Res 855:90–99PubMedCrossRef Berkowicz DA, Trombley PQ (2000) Dopaminergic modulation at the olfactory nerve synapse. Brain Res 855:90–99PubMedCrossRef
19.
Zurück zum Zitat Davila NG, Blakemore LJ, Trombley PQ (2003) Dopamine modulates synaptic transmission between rat olfactory bulb neurons in culture. J Neurophysiol 90:395–404PubMedCrossRef Davila NG, Blakemore LJ, Trombley PQ (2003) Dopamine modulates synaptic transmission between rat olfactory bulb neurons in culture. J Neurophysiol 90:395–404PubMedCrossRef
20.
Zurück zum Zitat Hsia AY, Vincent JD, Lledo PM (1999) Dopamine depresses synaptic inputs into the olfactory bulb. J Neurophysiol 82:1082–1085PubMedCrossRef Hsia AY, Vincent JD, Lledo PM (1999) Dopamine depresses synaptic inputs into the olfactory bulb. J Neurophysiol 82:1082–1085PubMedCrossRef
21.
Zurück zum Zitat Sallaz M, Jourdan F (1992) Apomorphine disrupts odour-induced patterns of glomerular activation in the olfactory bulb. NeuroReport 3:833–836PubMedCrossRef Sallaz M, Jourdan F (1992) Apomorphine disrupts odour-induced patterns of glomerular activation in the olfactory bulb. NeuroReport 3:833–836PubMedCrossRef
22.
Zurück zum Zitat Bohnen NI, Müller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL et al (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain 133:1747–1754PubMedPubMedCentralCrossRef Bohnen NI, Müller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL et al (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain 133:1747–1754PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337–341PubMedCrossRef Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337–341PubMedCrossRef
24.
Zurück zum Zitat Song S, Wang Q, Jiang L, Oyarzabal E, Riddick NV, Wilson B et al (2019) Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions. Brain Behav Immun 81:374–387PubMedPubMedCentralCrossRef Song S, Wang Q, Jiang L, Oyarzabal E, Riddick NV, Wilson B et al (2019) Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions. Brain Behav Immun 81:374–387PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Huot P, Fox SH, Brotchie JM (2011) The serotonergic system in Parkinson’s disease. Prog Neurobiol 95:163–212PubMedCrossRef Huot P, Fox SH, Brotchie JM (2011) The serotonergic system in Parkinson’s disease. Prog Neurobiol 95:163–212PubMedCrossRef
26.
Zurück zum Zitat Morais LH, Hara DB, Bicca MA, Poli A, Takahashi RN (2018) Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson’s disease. Behav Pharmacol 29:199–210PubMedCrossRef Morais LH, Hara DB, Bicca MA, Poli A, Takahashi RN (2018) Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson’s disease. Behav Pharmacol 29:199–210PubMedCrossRef
27.
Zurück zum Zitat Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601PubMedCrossRef Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601PubMedCrossRef
28.
Zurück zum Zitat Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653PubMedCrossRef Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653PubMedCrossRef
29.
Zurück zum Zitat Rumeau C, Nguyen DT, Jankowski R (2016) How to assess olfactory performance with the Sniffin’ Sticks test(®). Eur Ann Otorhinolaryngol Head Neck Dis 133:203–206PubMedCrossRef Rumeau C, Nguyen DT, Jankowski R (2016) How to assess olfactory performance with the Sniffin’ Sticks test(®). Eur Ann Otorhinolaryngol Head Neck Dis 133:203–206PubMedCrossRef
30.
Zurück zum Zitat Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T (2019) Updated Sniffin’ sticks normative data based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol 276:719–728PubMedCrossRef Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T (2019) Updated Sniffin’ sticks normative data based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol 276:719–728PubMedCrossRef
31.
Zurück zum Zitat Hummel T, Kobal G, Gudziol H, Mackay-Sim A (2007) Normative data for the “Sniffin’ Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 264:237–243PubMedCrossRef Hummel T, Kobal G, Gudziol H, Mackay-Sim A (2007) Normative data for the “Sniffin’ Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 264:237–243PubMedCrossRef
32.
Zurück zum Zitat Wen HB, Zhang ZX, Niu FS, Li L (2008) The application of Montreal cognitive assessment in urban Chinese residents of Beijing. Zhonghua Nei Ke Za Zhi 47:36–39PubMed Wen HB, Zhang ZX, Niu FS, Li L (2008) The application of Montreal cognitive assessment in urban Chinese residents of Beijing. Zhonghua Nei Ke Za Zhi 47:36–39PubMed
33.
Zurück zum Zitat Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738–1745PubMedPubMedCentralCrossRef Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738–1745PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699PubMedCrossRef Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699PubMedCrossRef
35.
Zurück zum Zitat Starkstein SE (2012) Apathy in Parkinson’s disease: diagnostic and etiological dilemmas. Mov Disord 27:174–178PubMedCrossRef Starkstein SE (2012) Apathy in Parkinson’s disease: diagnostic and etiological dilemmas. Mov Disord 27:174–178PubMedCrossRef
36.
Zurück zum Zitat Mele B, Merrikh D, Ismail Z, Goodarzi Z (2019) Detecting apathy in individuals with Parkinson’s disease: a systematic review. J Parkinsons Dis 9:653–664PubMedCrossRef Mele B, Merrikh D, Ismail Z, Goodarzi Z (2019) Detecting apathy in individuals with Parkinson’s disease: a systematic review. J Parkinsons Dis 9:653–664PubMedCrossRef
37.
Zurück zum Zitat Williams JB (2001) Standardizing the Hamilton depression rating scale: past, present, and future. Eur Arch Psychiatry Clin Neurosci 251(Suppl 2):Ii6-12PubMedCrossRef Williams JB (2001) Standardizing the Hamilton depression rating scale: past, present, and future. Eur Arch Psychiatry Clin Neurosci 251(Suppl 2):Ii6-12PubMedCrossRef
38.
39.
Zurück zum Zitat Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH (2007) The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord 22:2386–2393PubMedCrossRef Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH (2007) The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord 22:2386–2393PubMedCrossRef
40.
Zurück zum Zitat Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B et al (2010) Scales to assess sleep impairment in Parkinson’s disease: critique and recommendations. Mov Disord 25:2704–2716PubMedCrossRef Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B et al (2010) Scales to assess sleep impairment in Parkinson’s disease: critique and recommendations. Mov Disord 25:2704–2716PubMedCrossRef
41.
Zurück zum Zitat Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMedCrossRef Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMedCrossRef
42.
Zurück zum Zitat Johns MW (2000) Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 9:5–11PubMedCrossRef Johns MW (2000) Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 9:5–11PubMedCrossRef
43.
Zurück zum Zitat Walters AS, Frauscher B, Allen R, Benes H, Chaudhuri KR, Garcia-Borreguero D et al (2014) Review of severity rating scales for restless legs syndrome: critique and recommendations. Mov Disord Clin Pract 1:317–324PubMedPubMedCentralCrossRef Walters AS, Frauscher B, Allen R, Benes H, Chaudhuri KR, Garcia-Borreguero D et al (2014) Review of severity rating scales for restless legs syndrome: critique and recommendations. Mov Disord Clin Pract 1:317–324PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123PubMedCrossRef Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123PubMedCrossRef
45.
Zurück zum Zitat Herlofson K, Larsen JP (2002) Measuring fatigue in patients with Parkinson’s disease—the Fatigue Severity Scale. Eur J Neurol 9:595–600PubMedCrossRef Herlofson K, Larsen JP (2002) Measuring fatigue in patients with Parkinson’s disease—the Fatigue Severity Scale. Eur J Neurol 9:595–600PubMedCrossRef
46.
Zurück zum Zitat Guo P, Wang RD, Lian TH, Ding DY, Zhang YN, Zhang WJ et al (2020) Olfactory dysfunction and its association with neuropathologic proteins in cerebrospinal fluid from patients with Parkinson disease. Front Aging Neurosci 12:594324PubMedPubMedCentralCrossRef Guo P, Wang RD, Lian TH, Ding DY, Zhang YN, Zhang WJ et al (2020) Olfactory dysfunction and its association with neuropathologic proteins in cerebrospinal fluid from patients with Parkinson disease. Front Aging Neurosci 12:594324PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA et al (2009) Prevalence of smell loss in Parkinson’s disease—a multicenter study. Parkinsonism Relat Disord 15:490–494PubMedCrossRef Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA et al (2009) Prevalence of smell loss in Parkinson’s disease—a multicenter study. Parkinsonism Relat Disord 15:490–494PubMedCrossRef
48.
Zurück zum Zitat Trentin S, Fraiman de Oliveira BS, Ferreira Felloni Borges Y, de Mello Rieder CR (2022) Systematic review and meta-analysis of Sniffin Sticks Test performance in Parkinson’s disease patients in different countries. Eur Arch Otorhinolaryngol 279:1123–1145PubMedCrossRef Trentin S, Fraiman de Oliveira BS, Ferreira Felloni Borges Y, de Mello Rieder CR (2022) Systematic review and meta-analysis of Sniffin Sticks Test performance in Parkinson’s disease patients in different countries. Eur Arch Otorhinolaryngol 279:1123–1145PubMedCrossRef
49.
Zurück zum Zitat Doty RL (2012) Olfaction in Parkinson’s disease and related disorders. Neurobiol Dis 46:527–552PubMedCrossRef Doty RL (2012) Olfaction in Parkinson’s disease and related disorders. Neurobiol Dis 46:527–552PubMedCrossRef
50.
Zurück zum Zitat Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM et al (2016) Position paper on olfactory dysfunction. Rhinology 56:1–30PubMed Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM et al (2016) Position paper on olfactory dysfunction. Rhinology 56:1–30PubMed
51.
Zurück zum Zitat Doty RL, Wylie C, Potter M, Beston R, Cope B, Majam K (2019) Clinical validation of the olfactory detection threshold module of the Snap & Sniff® olfactory test system. Int Forum Allergy Rhinol 9:986–992PubMedCrossRef Doty RL, Wylie C, Potter M, Beston R, Cope B, Majam K (2019) Clinical validation of the olfactory detection threshold module of the Snap & Sniff® olfactory test system. Int Forum Allergy Rhinol 9:986–992PubMedCrossRef
52.
Zurück zum Zitat Boesveldt S, Verbaan D, Knol DL, Visser M, van Rooden SM, van Hilten JJ et al (2008) A comparative study of odor identification and odor discrimination deficits in Parkinson’s disease. Mov Disord 23:1984–1990PubMedCrossRef Boesveldt S, Verbaan D, Knol DL, Visser M, van Rooden SM, van Hilten JJ et al (2008) A comparative study of odor identification and odor discrimination deficits in Parkinson’s disease. Mov Disord 23:1984–1990PubMedCrossRef
53.
Zurück zum Zitat Baba T, Kikuchi A, Hirayama K, Nishio Y, Hosokai Y, Kanno S et al (2012) Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson’s disease: a 3 year longitudinal study. Brain 135:161–169PubMedCrossRef Baba T, Kikuchi A, Hirayama K, Nishio Y, Hosokai Y, Kanno S et al (2012) Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson’s disease: a 3 year longitudinal study. Brain 135:161–169PubMedCrossRef
54.
Zurück zum Zitat Morley JF, Weintraub D, Mamikonyan E, Moberg PJ, Siderowf AD, Duda JE (2011) Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson’s disease. Mov Disord 26:2051–2057PubMedPubMedCentralCrossRef Morley JF, Weintraub D, Mamikonyan E, Moberg PJ, Siderowf AD, Duda JE (2011) Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson’s disease. Mov Disord 26:2051–2057PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Baba T, Takeda A, Kikuchi A, Nishio Y, Hosokai Y, Hirayama K et al (2011) Association of olfactory dysfunction and brain. Metabolism in Parkinson’s disease. Mov Disord 26:621–628PubMedCrossRef Baba T, Takeda A, Kikuchi A, Nishio Y, Hosokai Y, Hirayama K et al (2011) Association of olfactory dysfunction and brain. Metabolism in Parkinson’s disease. Mov Disord 26:621–628PubMedCrossRef
56.
Zurück zum Zitat Masala C, Solla P, Liscia A, Defazio G, Saba L, Cannas A et al (2018) Correlation among olfactory function, motors’ symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson’s disease. J Neurol 265:1764–1771PubMedCrossRef Masala C, Solla P, Liscia A, Defazio G, Saba L, Cannas A et al (2018) Correlation among olfactory function, motors’ symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson’s disease. J Neurol 265:1764–1771PubMedCrossRef
57.
Zurück zum Zitat Fang TC, Chang MH, Yang CP, Chen YH, Lin CH (2021) The association of olfactory dysfunction with depression, cognition, and disease severity in Parkinson’s disease. Front Neurol 12:779712PubMedPubMedCentralCrossRef Fang TC, Chang MH, Yang CP, Chen YH, Lin CH (2021) The association of olfactory dysfunction with depression, cognition, and disease severity in Parkinson’s disease. Front Neurol 12:779712PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Verbaan D, Boesveldt S, van Rooden SM, Visser M, Marinus J, Macedo MG et al (2008) Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics? Neurology 71:1877–1882PubMedCrossRef Verbaan D, Boesveldt S, van Rooden SM, Visser M, Marinus J, Macedo MG et al (2008) Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics? Neurology 71:1877–1882PubMedCrossRef
59.
Zurück zum Zitat Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T (2010) Cognitive factors in odor detection, odor discrimination, and odor identification tasks. J Clin Exp Neuropsychol 32:1062–1067PubMedCrossRef Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T (2010) Cognitive factors in odor detection, odor discrimination, and odor identification tasks. J Clin Exp Neuropsychol 32:1062–1067PubMedCrossRef
60.
Zurück zum Zitat Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N et al (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73:273–278PubMedCrossRef Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N et al (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73:273–278PubMedCrossRef
61.
Zurück zum Zitat Takeda A, Baba T, Kikuchi A, Hasegawa T, Sugeno N, Konno M et al (2014) Olfactory dysfunction and dementia in Parkinson’s disease. J Parkinsons Dis 4:181–187PubMedCrossRef Takeda A, Baba T, Kikuchi A, Hasegawa T, Sugeno N, Konno M et al (2014) Olfactory dysfunction and dementia in Parkinson’s disease. J Parkinsons Dis 4:181–187PubMedCrossRef
62.
Zurück zum Zitat Lee EY, Eslinger PJ, Du G, Kong L, Lewis MM, Huang X (2014) Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson’s disease. Mov Disord 29:1205–1208PubMedPubMedCentralCrossRef Lee EY, Eslinger PJ, Du G, Kong L, Lewis MM, Huang X (2014) Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson’s disease. Mov Disord 29:1205–1208PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Cramer CK, Friedman JH, Amick MM (2010) Olfaction and apathy in Parkinson’s disease. Parkinsonism Relat Disord 16:124–126PubMedCrossRef Cramer CK, Friedman JH, Amick MM (2010) Olfaction and apathy in Parkinson’s disease. Parkinsonism Relat Disord 16:124–126PubMedCrossRef
64.
Zurück zum Zitat Hong JY, Sunwoo MK, Ham JH, Lee JJ, Lee PH, Sohn YH (2015) Apathy and olfactory dysfunction in early Parkinson’s disease. J Mov Disord 8:21–25PubMedPubMedCentralCrossRef Hong JY, Sunwoo MK, Ham JH, Lee JJ, Lee PH, Sohn YH (2015) Apathy and olfactory dysfunction in early Parkinson’s disease. J Mov Disord 8:21–25PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Solla P, Masala C, Liscia A, Piras R, Ercoli T, Fadda L et al (2020) Sex-related differences in olfactory function and evaluation of possible confounding factors among patients with Parkinson’s disease. J Neurol 267:57–63PubMedCrossRef Solla P, Masala C, Liscia A, Piras R, Ercoli T, Fadda L et al (2020) Sex-related differences in olfactory function and evaluation of possible confounding factors among patients with Parkinson’s disease. J Neurol 267:57–63PubMedCrossRef
66.
Zurück zum Zitat Martinez-Nunez AE, Latack K, Situ-Kcomt M, Mahajan A (2022) Olfaction and apathy in early idiopathic Parkinson’s disease. J Neurol Sci 439:120314PubMedCrossRef Martinez-Nunez AE, Latack K, Situ-Kcomt M, Mahajan A (2022) Olfaction and apathy in early idiopathic Parkinson’s disease. J Neurol Sci 439:120314PubMedCrossRef
67.
Zurück zum Zitat Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, Nithi K, Talbot K, Ben-Shlomo Y et al (2014) REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson’s disease. J Neurol Neurosurg Psychiatry 85:560–566PubMedCrossRef Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, Nithi K, Talbot K, Ben-Shlomo Y et al (2014) REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson’s disease. J Neurol Neurosurg Psychiatry 85:560–566PubMedCrossRef
68.
Zurück zum Zitat Jin H, Zhang JR, Shen Y, Liu CF (2017) Clinical significance of REM sleep behavior disorders and other non-motor symptoms of Parkinsonism. Neurosci Bull 33:576–584PubMedPubMedCentralCrossRef Jin H, Zhang JR, Shen Y, Liu CF (2017) Clinical significance of REM sleep behavior disorders and other non-motor symptoms of Parkinsonism. Neurosci Bull 33:576–584PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Schenck CH, Boeve BF, Mahowald MW (2013) Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 14:744–748PubMedCrossRef Schenck CH, Boeve BF, Mahowald MW (2013) Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 14:744–748PubMedCrossRef
70.
Zurück zum Zitat Kim YE, Jeon BS (2014) Clinical implication of REM sleep behavior disorder in Parkinson’s disease. J Parkinsons Dis 4:237–244PubMedCrossRef Kim YE, Jeon BS (2014) Clinical implication of REM sleep behavior disorder in Parkinson’s disease. J Parkinsons Dis 4:237–244PubMedCrossRef
71.
Zurück zum Zitat Lyu Z, Zheng S, Zhang X, Mai Y, Pan J, Hummel T et al (2021) Olfactory impairment as an early marker of Parkinson’s disease in REM sleep behaviour disorder: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 92:271–281PubMedCrossRef Lyu Z, Zheng S, Zhang X, Mai Y, Pan J, Hummel T et al (2021) Olfactory impairment as an early marker of Parkinson’s disease in REM sleep behaviour disorder: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 92:271–281PubMedCrossRef
72.
Zurück zum Zitat Shin JH, Lee JY, Kim YK, Shin SA, Kim H, Nam H et al (2020) Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. Neurology 95:e3081–e3092PubMedCrossRef Shin JH, Lee JY, Kim YK, Shin SA, Kim H, Nam H et al (2020) Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. Neurology 95:e3081–e3092PubMedCrossRef
73.
Zurück zum Zitat Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef
74.
Zurück zum Zitat Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W et al (2012) Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 27:617–626PubMedCrossRef Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W et al (2012) Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 27:617–626PubMedCrossRef
75.
Zurück zum Zitat Mazza S, Soucy JP, Gravel P, Michaud M, Postuma R, Massicotte-Marquez J et al (2006) Assessing whole brain perfusion changes in patients with REM sleep behavior disorder. Neurology 67:1618–1622PubMedCrossRef Mazza S, Soucy JP, Gravel P, Michaud M, Postuma R, Massicotte-Marquez J et al (2006) Assessing whole brain perfusion changes in patients with REM sleep behavior disorder. Neurology 67:1618–1622PubMedCrossRef
76.
Zurück zum Zitat Iranzo A, Graus F, Clover L, Morera J, Bruna J, Vilar C et al (2006) Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol 59:178–181PubMedCrossRef Iranzo A, Graus F, Clover L, Morera J, Bruna J, Vilar C et al (2006) Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol 59:178–181PubMedCrossRef
77.
Zurück zum Zitat Ogaki K, Fujita H, Nozawa N, Shiina T, Sakuramoto H, Suzuki K (2023) Factors contributing to sleep disturbances and excessive daytime sleepiness in patients with Parkinson’s disease. Front Neurol 14:1097251PubMedPubMedCentralCrossRef Ogaki K, Fujita H, Nozawa N, Shiina T, Sakuramoto H, Suzuki K (2023) Factors contributing to sleep disturbances and excessive daytime sleepiness in patients with Parkinson’s disease. Front Neurol 14:1097251PubMedPubMedCentralCrossRef
78.
Zurück zum Zitat Hu Y, Guo P, Lian TH, Zuo LJ, Yu SY, Liu L et al (2021) Clinical characteristics, iron metabolism and neuroinflammation: new insight into excessive daytime sleepiness in Parkinson’s disease. Neuropsychiatr Dis Treat 17:2041–2051PubMedPubMedCentralCrossRef Hu Y, Guo P, Lian TH, Zuo LJ, Yu SY, Liu L et al (2021) Clinical characteristics, iron metabolism and neuroinflammation: new insight into excessive daytime sleepiness in Parkinson’s disease. Neuropsychiatr Dis Treat 17:2041–2051PubMedPubMedCentralCrossRef
79.
Zurück zum Zitat Yang J, Lv DJ, Li LX, Wang YL, Qi D, Chen J et al (2019) Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson’s disease. Neurotoxicology 73:175–182PubMedCrossRef Yang J, Lv DJ, Li LX, Wang YL, Qi D, Chen J et al (2019) Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson’s disease. Neurotoxicology 73:175–182PubMedCrossRef
80.
Zurück zum Zitat Deeb J, Shah M, Muhammed N, Gunasekera R, Gannon K, Findley LJ et al (2010) A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson’s disease. QJM 103:941–952PubMedCrossRef Deeb J, Shah M, Muhammed N, Gunasekera R, Gannon K, Findley LJ et al (2010) A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson’s disease. QJM 103:941–952PubMedCrossRef
81.
Zurück zum Zitat Mundiñano IC, Caballero MC, Ordóñez C, Hernandez M, DiCaudo C, Marcilla I et al (2011) Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. Acta Neuropathol 122:61–74PubMedCrossRef Mundiñano IC, Caballero MC, Ordóñez C, Hernandez M, DiCaudo C, Marcilla I et al (2011) Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. Acta Neuropathol 122:61–74PubMedCrossRef
82.
Zurück zum Zitat Lelan F, Boyer C, Thinard R, Rémy S, Usal C, Tesson L et al (2011) Effects of human alpha-synuclein A53T–A30P mutations on SVZ and local olfactory bulb cell proliferation in a transgenic rat model of Parkinson disease. Parkinsons Dis 2011:987084PubMedPubMedCentral Lelan F, Boyer C, Thinard R, Rémy S, Usal C, Tesson L et al (2011) Effects of human alpha-synuclein A53T–A30P mutations on SVZ and local olfactory bulb cell proliferation in a transgenic rat model of Parkinson disease. Parkinsons Dis 2011:987084PubMedPubMedCentral
83.
Zurück zum Zitat Yamada M, Onodera M, Mizuno Y, Mochizuki H (2004) Neurogenesis in olfactory bulb identified by retroviral labeling in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated adult mice. Neuroscience 124:173–181PubMedCrossRef Yamada M, Onodera M, Mizuno Y, Mochizuki H (2004) Neurogenesis in olfactory bulb identified by retroviral labeling in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated adult mice. Neuroscience 124:173–181PubMedCrossRef
84.
Zurück zum Zitat Belzunegui S, San Sebastián W, Garrido-Gil P, Izal-Azcárate A, Vázquez-Claverie M, López B et al (2007) The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP. Synapse 61:1006–1012PubMedCrossRef Belzunegui S, San Sebastián W, Garrido-Gil P, Izal-Azcárate A, Vázquez-Claverie M, López B et al (2007) The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP. Synapse 61:1006–1012PubMedCrossRef
85.
Zurück zum Zitat Doty RL (2017) Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate? Lancet Neurol 16:478–488PubMedCrossRef Doty RL (2017) Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate? Lancet Neurol 16:478–488PubMedCrossRef
86.
Zurück zum Zitat Ohkuma M, Kawai F, Miyachi E (2013) Acetylcholine enhances excitability by lowering the threshold of spike generation in olfactory receptor cells. J Neurophysiol 110:2082–2089PubMedCrossRef Ohkuma M, Kawai F, Miyachi E (2013) Acetylcholine enhances excitability by lowering the threshold of spike generation in olfactory receptor cells. J Neurophysiol 110:2082–2089PubMedCrossRef
87.
Zurück zum Zitat Velayudhan L, Lovestone S (2009) Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. J Clin Psychopharmacol 29:387–390PubMedCrossRef Velayudhan L, Lovestone S (2009) Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. J Clin Psychopharmacol 29:387–390PubMedCrossRef
88.
Zurück zum Zitat Zhang S, Xiao Q, Le W (2015) Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein. PLoS ONE 10:e0119928PubMedPubMedCentralCrossRef Zhang S, Xiao Q, Le W (2015) Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein. PLoS ONE 10:e0119928PubMedPubMedCentralCrossRef
89.
Zurück zum Zitat Versace V, Langthaler PB, Sebastianelli L, Höller Y, Brigo F, Orioli A et al (2017) Impaired cholinergic transmission in patients with Parkinson’s disease and olfactory dysfunction. J Neurol Sci 377:55–61PubMedCrossRef Versace V, Langthaler PB, Sebastianelli L, Höller Y, Brigo F, Orioli A et al (2017) Impaired cholinergic transmission in patients with Parkinson’s disease and olfactory dysfunction. J Neurol Sci 377:55–61PubMedCrossRef
90.
Zurück zum Zitat Oh E, Park J, Youn J, Kim JS, Park S, Jang W (2017) Olfactory dysfunction in early Parkinson’s disease is associated with short latency afferent inhibition reflecting central cholinergic dysfunction. Clin Neurophysiol 128:1061–1068PubMedCrossRef Oh E, Park J, Youn J, Kim JS, Park S, Jang W (2017) Olfactory dysfunction in early Parkinson’s disease is associated with short latency afferent inhibition reflecting central cholinergic dysfunction. Clin Neurophysiol 128:1061–1068PubMedCrossRef
91.
Zurück zum Zitat Suzuki Y, Kiyokage E, Sohn J, Hioki H, Toida K (2015) Structural basis for serotonergic regulation of neural circuits in the mouse olfactory bulb. J Comp Neurol 523:262–280PubMedCrossRef Suzuki Y, Kiyokage E, Sohn J, Hioki H, Toida K (2015) Structural basis for serotonergic regulation of neural circuits in the mouse olfactory bulb. J Comp Neurol 523:262–280PubMedCrossRef
92.
Zurück zum Zitat Jovanovic H, Perski A, Berglund H, Savic I (2011) Chronic stress is linked to 5-HT(1A) receptor changes and functional disintegration of the limbic networks. Neuroimage 55:1178–1188PubMedCrossRef Jovanovic H, Perski A, Berglund H, Savic I (2011) Chronic stress is linked to 5-HT(1A) receptor changes and functional disintegration of the limbic networks. Neuroimage 55:1178–1188PubMedCrossRef
Metadaten
Titel
Clinical features and neurobiochemical mechanisms of olfactory dysfunction in patients with Parkinson disease
verfasst von
Ruidan Wang
Tenghong Lian
Mingyue He
Peng Guo
Shuyang Yu
Lijun Zuo
Yang Hu
Wei Zhang
Publikationsdatum
27.12.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 4/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-023-12122-1

Weitere Artikel der Ausgabe 4/2024

Journal of Neurology 4/2024 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.